| Literature DB >> 29866120 |
Ann F Chou1, Juell B Homco2, Zsolt Nagykaldi3, James W Mold3, F Daniel Duffy2, Steven Crawford3, Julie A Stoner4.
Abstract
BACKGROUND: Cardiovascular disease (CVD) is the leading cause of death in the US and incurs high health care costs. While many initiatives promote the implementation of ABCS (aspirin therapy, blood pressure control, cholesterol management, and smoking cessation) measures, most primary care practices (PCPs) lack quality improvement (QI) support and resources to achieve meaningful targets. The Healthy Hearts for Oklahoma (H2O) Study proposes to build a QI infrastructure by (1) constructing a sustainable Oklahoma Primary Healthcare Improvement Collaborative (OPHIC) to support dissemination and implementation (D&I) of QI methods; (2) providing QI support in PCPs to better manage patients at risk for CVD events. Parallel to infrastructure building, H2O aims to conduct a comprehensive evaluation of the QI support D&I in primary care and assess the relationship between QI support uptake and changes in ABCS measures.Entities:
Keywords: Cardiovascular disease; Implementation and dissemination; Patient-centered outcomes; Practice facilitation; Primary care; Quality improvement
Mesh:
Year: 2018 PMID: 29866120 PMCID: PMC5987433 DOI: 10.1186/s12913-018-3189-4
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Conceptual model for implementation strategy
Fig. 2Primary care practices servicing adults in Oklahoma Counties
Fig. 3Logic model
Definitions for Consolidated Framework for Implementation Research (CFIR) Domains
| CFIR Domain | Definition |
|---|---|
| Innovation characteristics | Innovation characteristics include the innovation itself, evidence strength and quality, relative advantage, complexity, design quality and packaging, etc. The innovation in this context is the implementation support strategy. For the purpose of this project, we will measure two characteristics of the implementation support strategy: complexity and relative advantage. |
| Characteristics of the individual implementer | Characteristics of clinicians and staff in a given practice who implement the support strategy include knowledge and understanding of the strategy, mindfulness, and personal attributes such as attitude, motivation, values, competency capacity, and learning style. |
| Inner setting | Organizational structure and mechanisms describe practices’ teamwork and communications, organizational culture, climate and readiness for implementation. Organizational climate illustrates practices’ tension for change, relative priority, incentives and rewards, goals and feedback, and learning. |
| Environment | The environment takes into account the location where the practice is situated, and the practice’s relationships with other organizations such as membership in a quality improvement network, health system, or professional society. |
| Process of implementation | The implementation process involves 4 stages: planning, engaging, executing, and reflecting and evaluating. Practices will work with ADs and PFs to select scheme, methods, and tasks for implementing the ABCS during the planning stage. The planning is followed by engaging the opinion leaders, internal implementation leaders, champions, and external change agents. The implementation plan is executed and evaluated with quantitative and qualitative feedback about the progress and quality of implementation. |
Abbreviations: ABCS aspirin, blood pressure, cholesterol and smoking measures, AD academic detailer, PF practice facilitator
Fig. 4Stepped wedge cluster randomized study design
Outcome measures from HIE and/or EHR data
| Measure (Source) | Numerator | Denominator* | Exclusion | Data Source |
|---|---|---|---|---|
| Aspirin (PQRS 204/NQF 0068) | Patients in denominator with documented use of aspirin or other antithrombotic | Patients 18+ years of age with Ischemic Vascular Disease diagnosis, or hospital discharge for acute myocardial infarction, coronary artery bypass graft, or percutaneous coronary interventions | On another anticoagulant, GI bleeding history, aspirin allergy | Health Information Exchange (HIE) |
| Blood Pressure Management 1 (PQRS 236/NQF 0018) | Patients in denominator whose blood pressure was adequately controlled (< 140/90) | Patients aged 18 through 85 years with a diagnosis of hypertension | End stage renal disease, dialysis, renal transplant, or diagnosis of pregnancy | HIE |
| Blood Pressure Management 2 | Patients in denominator whose blood pressure was adequately controlled (age 18–59 and/or people with diabetes or chronic kidney disease < 140/90; age 60–85 < 150/90) | Patients aged 18 through 85 with a diagnosis of hypertension | Lacking a DM or CKD diagnosis | HIE |
| Cholesterol Management 1 (PQRS 316) | Patients in the denominator whose risk-stratified fasting LDL is at or below the recommended LDL goal | Patients aged 20 through 79 years of age who had a fasting LDL performed | HIE and chart audits | |
| Cholesterol Management 2 | Patients in the denominator who were prescribed the recommended dose of statin based on risk status | Patients aged 20 through 79 years of age who had a fasting LDL performed | HIE and chart audits | |
| Smoking Cessation Support (PQRS 226/NQF 0028) | Patients in denominator who were screened about tobacco use one or more times within 24 months AND who received tobacco cessation counseling intervention if identified as a tobacco user | Patients age 18+ years | Documentation of medical reason(s) for not screening for tobacco use | HIE |
*Note: Population denominators will be based on active patient—defined as patients who have been seen in the practice within the previous 18 months
Abbreviations: CABG coronary artery bypass grafting, CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVA cerebral vascular accident, DM diabetes mellitus, ED emergency department, GI gastric intestinal, LDL low-density lipoprotein, LOS length of stay, MI myocardial infarction, PQRS physician quality reporting system, NQF National Quality Forum
Summary of the assumed intervention effect sizes and power
| Endpoint | Patient Cohort Characteristics (defining cohort eligible for intervention) | Baselinea Percentage | Post-intervention Percentage | Power |
|---|---|---|---|---|
| A: Aspirin (aspirin or other antithrombotic prescribed) | Aged 18 years and older with ischemic vascular disease without a contraindication to aspirin | 60% | 70% | > 95% |
| B1: Blood Pressure Management 1 (blood pressure adequately controlled) | Aged 18–85 who had a diagnosis of hypertension | 65% | 70% | > 95% |
| B2: Blood Pressure Management 2 (blood pressure adequately controlled as per co-morbidity-adjusted targets) | Aged 18–85 who had a diagnosis of hypertension | 65% | 70% | > 95% |
| C1: Cholesterol Management 1:** | Aged 20–79 | 15% | 25% | > 95% |
| C2: Cholesterol Management 2:** | Aged 20–79 | 15% | 25% | > 95% |
| S: Smoking cessation support (screening about tobacco AND received cessation counseling if tobacco user) | Aged 18 years and older | 60% | 70% | > 95% |
aEstimates for the baseline percentages for aspirin use, blood pressure management, and smoking cessation support are based on Oklahoma Foundation for Medical Quality (OFMQ) primary care practice initiatives in the state of Oklahoma
**The C1 and C2 measures were calculated as the product of the probability of having a fasting LDL test (estimated to be 0.3) multiplied by the probability of having an LDL measure below the target (estimated to be 0.50) or being prescribed a statin if indicated (estimated to be 0.5) conditional on having a fasting LDL test
Abbreviation: LDL low-density lipoprotein